Can TAF Treat Hepatitis B Cirrhosis?

Tenofovir Alafenamide (TAF) is a nucleoside analog antiviral medication known for its potent viral suppression, minimal side effects, and low risk of drug resistance. As a result, it is considered one of the most effective treatments for hepatitis B-related cirrhosis. Chronic hepatitis B can lead to persistent liver inflammation, fibrosis, and eventually cirrhosis due to continuous viral replication. The key to managing this condition lies in long-term and effective suppression of the hepatitis B virus (HBV), which helps reduce liver damage, slow disease progression, and lower the risk of complications such as liver cancer and hepatic decompensation.

In addition to antiviral therapy, patients with impaired liver function may benefit from liver-protecting medications used in combination with TAF. This dual approach can accelerate liver function recovery. Once liver enzymes stabilize, TAF monotherapy is usually sufficient. It should be taken with food to enhance absorption, and patients must maintain a consistent daily schedule to avoid missed or skipped doses. It's important to note that antiviral drugs like TAF do not eliminate the virus entirely. Even when viral DNA becomes undetectable, lifelong treatment is necessary to prevent viral rebound, which could lead to severe liver damage or even death.

Furthermore, regular medical follow-ups are essential to monitor treatment effectiveness and screen for hepatocellular carcinoma. Ongoing surveillance ensures early detection of any potential complications, improving long-term outcomes for individuals living with hepatitis B cirrhosis.